{"id":41916,"date":"2019-04-07T11:56:32","date_gmt":"2019-04-07T09:56:32","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=41916"},"modified":"2019-04-07T11:57:27","modified_gmt":"2019-04-07T09:57:27","slug":"una-casa-farmaceutica-creava-dipendenza-dagli-antidolorifici-e-poi-vendeva-la-cura","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/una-casa-farmaceutica-creava-dipendenza-dagli-antidolorifici-e-poi-vendeva-la-cura\/","title":{"rendered":"A drug company was addictive to painkillers and then sold the cure"},"content":{"rendered":"<h2 class=\"article-page__header-subtitle selectionShareable\">According to an investigation by the New York prosecutor&#039;s office, the Sackler family, producers of OxyContin, were aware that they were doing business by exploiting the addiction that the drug induces in patients<\/h2>\n<p><a href=\"https:\/\/www.agi.it\/estero\/scandalo_antidolorifici_usa-5253754\/news\/2019-04-03\/\" target=\"_blank\" rel=\"noopener\">AGI health<\/a> | Of<a class=\"h-unstyled-link\" href=\"https:\/\/www.agi.it\/authors\/massimo-basile\/\" target=\"_blank\" rel=\"noopener\"> <span class=\"article-page__header-byline-author\">Massimo Basile<\/span> <\/a>\u00a0| 03 April 2019,<\/p>\n<p class=\"selectionShareable\">After making more than four billion dollars from the sale of an addictive opioid drug, they would discover a new business: selling drugs to treat addiction. This would be the plan set up by the family <strong>Sackler<\/strong>, owner for generations of <strong>Purdue Pharma<\/strong>, the pharmaceutical industry that built its recent fortunes off the sale <a href=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/oxycontin-purdue-opioid.png\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-41918 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/oxycontin-purdue-opioid.png\" alt=\"\" width=\"473\" height=\"303\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/oxycontin-purdue-opioid.png 772w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/oxycontin-purdue-opioid-300x192.png 300w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/oxycontin-purdue-opioid-768x492.png 768w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/oxycontin-purdue-opioid-179x116.png 179w\" sizes=\"auto, (max-width: 473px) 100vw, 473px\" \/><\/a>of the<a href=\"https:\/\/www.oxycontin.com\/\" target=\"_blank\" rel=\"noopener\"><strong>OxyContin<\/strong><\/a>, a more potent analgesic than morphine, which is addictive.<\/p>\n<p class=\"selectionShareable\">This is what emerges, according to the <a href=\"http:\/\/www.nytimes.com\/2019\/04\/01\/health\/sacklers-oxycontin-lawsuits.html\" target=\"_blank\" rel=\"noopener\">New York Times<\/a>, from the investigation that the New York State Attorney&#039;s Office has opened to shed light on the circle of companies, including some off-shore ones, in which the family&#039;s revenues, approximately 13 billion dollars, have ended up in recent years. The Sacklers are a historic family of<strong> Brooklyn<\/strong>, formed by doctors, scholars and philanthropists: among the beneficiaries of their rich donations, the<strong> MoMa<\/strong> of New York, to the point that a wing of the contemporary art museum bears the name of the family.<\/p>\n<p class=\"selectionShareable\">But in the field of business the Sacklers have shown another face: as appears from some documents in the hands of the prosecution, gathered under the name of &quot;<strong>Tango Project<\/strong>\u201c, the company was aware of doing business by exploiting the addiction that their own drugs induce in patients: \u201cPain treatment and addiction are naturally linked\u201d, reads the document. The scheme envisaged the diffusion of the drug to relieve pain and then, generating dependence of the patient, placing another drug on the market to relieve the addiction.<\/p>\n<p class=\"selectionShareable\"><a href=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/Sackler-Purdue-Pharma.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-41920 alignleft\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/Sackler-Purdue-Pharma-683x1024.jpg\" alt=\"\" width=\"149\" height=\"224\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/Sackler-Purdue-Pharma-683x1024.jpg 683w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/Sackler-Purdue-Pharma-200x300.jpg 200w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/Sackler-Purdue-Pharma-768x1151.jpg 768w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/Sackler-Purdue-Pharma-1025x1536.jpg 1025w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/04\/Sackler-Purdue-Pharma.jpg 1366w\" sizes=\"auto, (max-width: 149px) 100vw, 149px\" \/><\/a>In the crosshairs every type of patient, from the &quot;fifty-year-old woman with <strong>chronic pains<\/strong> to the back \u2013 reads an internal document \u2013 to the eighteen-year-old athlete returning from<strong> injury<\/strong>from the richest to the poorest&quot;. The family&#039;s lawyers have denied any intent on the part of the Sacklers to monetize the<strong> side effects<\/strong> of drugs, contesting the hypothesis of having deliberately favored the phenomenon of addiction to increase business.<\/p>\n<p class=\"selectionShareable\">Since OxyContin hit the market, more than 200,000 Americans have died from it <strong>overdose<\/strong> linked to the prescription of opioids, a disturbing fact which \u2013 according to the New York Times \u2013 could turn out to be bad publicity for the product. The strategy would have been to blame the patients. \u201cWe must hammer those who abuse it in every way \u2013 he would have said<strong> Richard Sackler<\/strong>, addressing his employees \u2013 they are the culprits and the problem. They are reckless criminals.&quot;<\/p>","protected":false},"excerpt":{"rendered":"<p>Secondo un&#8217;inchiesta della Procura di New York, la famiglia Sackler, produttrice dell&#8217;OxyContin, era consapevole di fare affari sfruttando la dipendenza che il farmaco induce nei pazienti AGI salute | di Massimo Basile \u00a0| 03 aprile 2019, Dopo aver guadagnato pi\u00f9\u00a0di quattro miliardi di dollari dalla vendita di un farmaco a base di oppioidi, che generava &hellip;<\/p>","protected":false},"author":4,"featured_media":41922,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-41916","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/41916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=41916"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/41916\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/41922"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=41916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=41916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=41916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}